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SURGERY FOR ACQUIRED 
HEART DISEASE 
HOMOGRAFT REPLACEMENT 
OF THE MITRAL VALVE 
Graft selection, technique 
of implantation, and 
results in forty-three 
patients 
Because of experience gained in reconstructive mitral valve surgery, we have 
reevaluated the implantation of cryopreserved homografts in the mitral 
position. Forty-three patients, aged 11 to 69 years (mean 34 years), underwent 
mitral valve replacement with cryopreserved mitral homografts. The indica- 
tions for the procedure were acute endocarditis (n = 14), rheumatic stenosis 
(n = 26), systemic lupus endocarditis (n = 2), and marasmic endocarditis (n = 
1). All homografts were obtained from hearts explanted in the course of 
transplantation a d were cryopreserved at - 160 ° C in 10% dimethyl sulfoxide 
solution without antibiotics. Appropriate sizing was based on morphologic 
study of the homografts and preoperative echocardiographic assessment of the 
recipient valve. In 82 homografts analyzed, the height of the anterior leaflet 
was 25 - 3 mm and the distance from the anulus to the apex of the anterior 
papillary muscle was 21 _ 3 mm. The morphologic features of the papillary 
muscles were classified according to four types of increasing complexity. Nine 
valves with complex (type IV) papillary muscle abnormalities were discarded. 
Echocardiographic measurements of the valve were matched with those of the 
homograft identification cards and a slightly larger homograft was selected 
(measurements + 3 mm). Partial homograft replacement was done in case of 
a localized lesion (abscess or calcification) (n = 21). Total homograft replace- 
ment was undertaken i  the presence of diffuse lesions (n = 22). Two hospital 
deaths occurred as a result of poor cardiac output. One patient required 
reoperation on the tenth postoperative day after a dehiscence on the valvular 
suture line. After a mean follow-up of 14 months, there has been one late death 
caused by a bronchial neoplasm and one reoperation for residual stenosis 
(partial replacement). The remaining patients were in either New York Heart 
Association class I (n = 25) or I I  (n = 13). Thirty-three patients were in sinus 
rhythm. Follow-up echocardiography as revealed no mitral regurgitation 
(n = 20), minimal mitral regurgitation ( = 13), and mild mitral regurgitation 
(n = 5). Surface valve area has been calculated at 2.5 _ 0.4 cm 2 in partial 
homograft reconstruction and 2.7 - 0.3 cm 2 in total homograft replacement, 
with a transvalvular g adient of 3 -+ 4 mm Hg. Conclusion: In a selected group 
of patients, the use of mitral homografts ignificantly extended the present 
limitations of reparative surgery of the mitral valve. (J THORAC CARDIOVASC 
SURG 1996;111:367-80) 
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T he replacement of the mitral valve with a ho- mograft was one of the first operations conceived 
in the development of valvular surgery. Experimen- 
tal studies in the early 1960s in animal models 1-3 
bore encouraging results showing rapid integration 
of the homograft, whose leaflets and chordae re- 
mained intact 1 year after implantation (Fig. 1). 
Nonetheless, the first attempts to replace the mitral 
valve with a mitral homograft in a clinical situation 
met with early failure owing to misunderstanding of 
valvular function and difficulty in fixation of the 
homograft papillary muscle. 4-7 Progress achieved 
over the past 20 years in the assessment of the mitral 
valve by means of echocardiography greatly im- 
proved knowledge of valvular physiopathology. 8' 9 
Simultaneously, experience gained in reconstructive 
surgery of the mitral valve has enabled surgeons to 
become more familiar with operative techniques 
involving the subvalvular apparatus, z° On the basis 
of general principles established by Carpentier 1° for 
mitral valve reconstruction, we reconsidered the use 
of a homograft for mitral valve replacement. Pre- 
liminary animal studies have allowed us to develop a 
reliable technique of implantation of the homograft 
papillary muscle (Fig. 1). Accordingly, we have 
evaluated the use of a homograft for partial or total 
replacement of the mitral valve in a series of 43 
patients. 
Patients and methods 
Homograft assessment and storage. Of a total of 82 
mitral homografts obtained from hearts explanted at the 
time of cardiac transplantation, 67valves were saved for 
implantation and 15 were discarded because of either 
structural abnormalities or positive viral serologic status. 
The entire mitral pparatus was dissected free including 
both the attachment of the papillary muscles onto the 
ventricular wall and the myocardium surrounding the 
mitral anulus. Care was taken in dissection of the aorto- 
mitral triangular area to ensure that an aortic homograft 
could also be harvested. This dissection was performed in 
a sterile theater. Cryopreservation was performed within 
18 hours of retrieval of the homograft in the tissue bank of 
H6pital St. Louis. A preservative solution containing 5% 
dimethyl sulfoxide without antibiotics was used and the 
temperature was gradually decreased by means of vapor- 
ized nitrogen to -150 ° C. 
The morphologic haracteristics of the papillary mus- 
cles and the distribution of the chordae were noted for 
each homograft and recorded on a specifically designed 
identification card (Fig. 2). Valve characteristics noted 
included the height of the anterior leaflet, the area of the 
anterior leaflet as measured with an annuloplasty ring 
obturator (Carpentier; Baxter Healthcare Corp., Edwards 
Div., Santa Ana, Calif.), and the distance between the 
apex of the papillary muscle and the mitral anulus (Fig. 2). 
Fig. 1. Mitral homograft 10 months after implantation i
a goat. Note normal leaflet tissue and chordae with 
moderate fibrosis of papillary muscles. 
Each papillary muscle was classified according to mor- 
phologic features into four types of increasing complexity 
(Fig. 3). The shape of the papillary muscle was not 
considered, but the classification was based on the exis- 
tence or nonexistence of a division in the muscle and its 
location with respect o the commissure: type I, simple 
single muscle; type II, divided muscle in a sagittal plane 
forming an individual head supporting chordae of the 
posterior leaflet; type III, divided muscle in a coronal 
plane forming an individual head supporting the commis- 
sural area of the leaflet (Fig. 3); and type IV, divided 
muscle with multiple heads originating at different levels 
on the ventricular wall from the apex to the base. The 
commissural chordae of type IV are short, originating 
from an isolated muscular band close to the mitral anulus. 
The remaining portions of papillary muscle had their 
insertion from a lower level on the ventricular wall. 
Morphologic type and a schematic representation f the 
cross section of each papillary muscle were included in the 
homograft identification card (Fig. 2). 
Indications. Forty-three patients aged 11 to 69 years 
(mean age 34 + 5 years) underwent partial (n = 21) or 
total (n -- 22) mitral valve replacement with a cryopre- 
served homograft. The indications for operation were as 
follows: rheumatic mitral stenosis (n = 26), acute infective 
endocarditis (n = 14), systemic lupus endocarditis (n = 2), 
and marasmic endocarditis (n = 1). In all patients with 
calcific mitral stenosis the indication was symptomatic 
effort intolerance (New York Heart Association class II or 
III), with antecedent pulmonary edema in 15 patients. 
In the patients with acute bacterial endocarditis, the 
indication for operation was hemodynamic instability with 
severe mitral insufficiency (n = 8), systemic embolism 
(n = 5), large mobile vegetations viewed at echocardiog- 
raphy (n = 2), and persistent septicemia despite maximal 
antibiotic therapy (n = 2). Operations were performed 
5 _+ 3 days after the start of antibiotic therapy. 
Preoperative lectrocardiograms demonstrated sinus 
rhythm in 32 patients and atrial fibrillation in eight 
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Fig. 2. Identification card with mean dimensions of 82 mitral homografts: height of the anterior leaflet, 25 
mm distance between anulus and papillary muscle (anterior 21 mm and posterior 26 mm), schematic 
representation f cross section of papillary muscles, morphologic type of papillary muscles, and dimensions 
according to Carpentier ring obturator. 
TYPE I TYPE  II 
O Qo 
TYPE III TYPE  IV 
L 1 
Fig. 3. Classification of papillary muscles (cross-sectional views are shown below the main diagram). TYPE 
/, Simple, single muscle; TYPE II, division in the sagittal plane forming an individual head supporting the 
posterior leaflet; TYPE III, division in the coronal plane forming an individual head supporting a 
commissure; TYPE/V,, divisions with multiple levels of origin from the ventricular wall. Short commissural 
chordae inserted on an isolated muscular band. 
patients. Nine of the procedures were reoperations: com- 
missurotomy (n = 2), mitral valve repair (n = 4), and 
prosthetic valve replacement (n = 3). All these patients 
had a total homograft insertion. 
All patients had given informed consent o the pro- 
posed operation. 
Preoperative echocardiographic assessment. All pa- 
tients had a preoperative transthoracic and transesopha- 
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Fig. 4. Echocardiographic measurements of the valve via a sagittal view (aortic valve and papillary muscle 
were visible). Height of the anterior leaflet (H) was measured in diastole (a). In systole, anteroposterior 
diameter of the anulus (•) was measured (b), as well as distance (D) between anulus and papillary muscle (c). 
geal echocardiogram. This confirmed the need for a 
homograft, he native valve being shown to be irreparable 
by means of existing methods of repair. The preoperative 
echocardiogram guided surgical strategy; partial or total 
homograft replacement was performed on the basis of the 
extent of the lesion. 
The size of the homograft was chosen according to 
measurements aken with the aid of the preoperative 
echocardiogram (Fig. 4). These parameters were mea- 
sured on a sagittal view of the mitral valve passing through 
the papillary muscles and aortic orifice. In diastole the 
height of the anterior leaflet was measured. In systole the 
plane of the anulus was defined by joining the insertions of 
both leaflets, allowing measurement of the anteroposte- 
riot diameter of the orifice. The distance separating the 
plane of the anulus and the apex of the papillary muscle 
was measured (the anterior papillary muscle being closest 
to the anulus was taken as a reference) (Fig. 4). 
These parameters were matched with those on the 
homograft identification card and a homograft slightly 
larger than the valve (measurements + 3 mm) was 
selected. For three patients who had undergone previous 
prosthetic mitral valve replacement, he sole criterion 
used for selection of an appropriate homograft was the 
diameter of the prosthesis, which was matched with the 
anterior leaflet height. 
Surgical technique 
Preparation of the homografl. The homograft was pre- 
pared before cardiopulmonary b pass was instituted. The 
homograft was thawed in the operating room at 40 ° C and 
then rinsed in successive baths of saline solution contain- 
ing decreasing concentrations of dimethyl sulfoxide. First, 
the ventricular muscle inserted to the anulus of the valve 
was dissected off without traumatizing the valve tissue, 
particular care being taken in the commissural areas. 
Then the wall of the left atrium attached to the anulus was 
excised. The connective tissue of the right and left tri- 
gones, which were frequently the site of a fibrocalcareous 
nodule, was trimmed. Finally, the fatty tissue in the 
atrioventricular junction was removed. 
Before the papillary muscles were prepared, their mor- 
phologic features were examined and noted to ensure that 
the orientation would be maintained at the time of 
implantation. In cases of divided papillary muscles, su- 
tures were placed to preserve the respective positions of 
the different heads. Each papillary muscle was detached 
from its insertion into the ventricular wall, with approxi- 
mately 15 mm of muscular tissue left beyond the origin of 
the chordae. The valve was then placed in a container of 
saline solution until its use. 
Technique of insertion of the mitral homografl. Myocar- 
dial protection was achieved with cold cardioplegic solu- 
tion injected into the aortic root. The left atrium was 
approached via the classic parallel incision in the inter- 
atrial sulcus. The mitral valve was inspected to assess the 
pathologic process and to decide which operative tech- 
nique would be necessary. In the presence of an isolated 
lesion affecting less than half of the valve (calcification or 
valvular abscess), only part of the homograft was inserted 
provided that the remainder of the valve was normal (n = 
21). On the other hand, in the presence of extensive 
lesions involving the entire valve, total homograft replace- 
ment was performed (n = 22). 
First, the pathologic valve tissue was excised (Fig. 5) 
and the relevant chordae divided at their insertion. The 
integrity of the papillary muscles was carefully preserved. 
These were mobilized by dividing the muscular bands 
attaching them to the ventricular wall (Fig. 5). The 
homograft implantation was then commenced by fixation 
of the papillary muscles starting with the posterior one. 
The exposure of the recipient papillary muscle was opti- 
mized by applying entle traction on a stay suture placed 
at this level. Each homograft papillary muscle was in- 
serted into the slit between the native papillary muscle 
and the wall of the left ventricle (Fig. 5). Great care was 
taken to maintain the respective positions of the different 
heads. The head supporting the commissure was used as a 
reference point and was positioned at the corresponding 
site on the native papillary muscle. This site was easily 
identified because the commissural chordae invariably 
originate from the apex of the papillary muscle. 
As a general rule, the papillary muscle of the homograft 
was sutured side to side at a slightly lower level on the 
recipient. A double row of sutures was used to implant he 
papillary muscle (Fig. 5). First, several mattress utures 
were placed at the base of the graft papillary muscle; 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 2 
Acar et aL 371 
second, multiple interrupted sutures around the margins 
of the graft and then the apex were used to attach it firmly 
to the native papillary muscle. The sutures were placed so 
as not to interfere with the origin of the chordae, inas- 
much as this could eventually lead to chordal erosion (Fig. 
5). At the level of emergence of the chordae the problem 
was avoided by using sutures in a vertical mattress pattern. 
For all the sutures the knots abutted on the native 
papillary muscle and pledgets were not used. 
The homograft leaflet tissue was then sutured circum- 
ferentially to the mitral anulus with continuous 5-0 Pro- 
lene polypropylene suture (Ethicon, Inc., Somerville, 
N.J.). The various portions of the valve were attached in 
the following order: (1) posteromedial commissure, (2) 
anterior leaflet, (3) anterolateral commissure, and (4) 
posterior leaflet. Particular attention was taken in posi- 
tioning the commissures ( ee Fig. 5), and the suture was 
effected without ension in the areas of the anterior leaflet 
and commissures. In cases of excess or deficient ho- 
mograft leaflet issue with respect o the mitral anulus, the 
suturing style was modified to achieve quilibration while 
the posterior leaflet was being attached (Fig. 5). 
In all cases, a remodeling annuloplasty was performed 
with a prosthetic ring (Carpentier ing, Classic n = 40, 
Physio n = 3; Baxter). The sutures for the annuloplasty 
ring were placed before the valve leaflet tissue was 
attached. The size of the annuloplasty ring was chosen 
according to the size of the anterior leaflet of the ho- 
mograft measured with an obturator. After placement 
of the homograft, the final result was evaluated by 
infusion of saline solution under pressure into the 
ventricle (Fig. 5). 
Partial homografi replacement. All affected areas of the 
mitral valve leaflets and the subvalvular apparatus were 
excised and a portion equivalent to 25% to 50% of the 
valve was replaced. The sites of partial homograft replace- 
ment were the anterolateral commissure/hemivalve ar a 
(n = 10), the posteromedial commissure/hemivalve ar a 
(n = 7), and the anterior leaflet necessitating the implan- 
tation of both papillary muscles (n = 4) (Fig. 6). 
A corresponding portion of homograft, slightly larger to 
obtain a mild excess of tissue, was used for reconstruction 
(Figs. 7 and 8). The technique of implantation was as 
already described for the total homograft: implantation 
first of the papillary muscle, followed by attachment of the 
homograft leaflet tissue to the mitral anulus and the 
remaining portions of the native valve (Figs. 7 and 8). An 
annuloplasty ring was placed in all cases, the size depend- 
ing on that of the reconstituted anterior leaflet. 
Operative details. Duration of cardiopulmonary b pass 
times for partial homograft reconstruction was 105 -+ 20 
minutes and for total homograft replacement, 118 +- 15 
minutes. An associated procedure was performed in eight 
cases and included aortic valve repair (n = 3), tricuspid 
valve repair (n = 1), aortic valve replacement with a 
homograft (n = 2), and tricuspid valve replacement with a 
mitral homograft (n = 2). 
Clinical follow-up. All patients underwent intraopera- 
tive transesophageal chocardiography with a multiplanar 
probe and transthoracic echocardiography 2 months after 
the operation. After a follow-up of between 3 and 34 
months (mean 14 +_ 3 months), all the patients were 
examined and a transthoracic echocardiogram was per- 
formed. 
Results 
Anatomic characteristics of homografts (n = 82). 
The height of the anterior leaflet was 25 _+ 3 mm (20 
to 31 ram). The mean distance separating the mitral 
anulus from the apex of the anterior papillary muscle 
was 21 _+ 3 mm and from the apex of the posterior 
papillary muscle, 26 _+ 4 mm (see Fig. 2). The anterior 
papillary muscles were classified morphologically as 
follows: type I, n = 47; type II, n = 12; type III, n = 14; 
and type IV, n = 9. The posterior papillary muscles 
were classified as follows: type I, n = 43; type II, n = 
22; type III, n = 7; and type IV, n = 10. Type IV 
papillary muscles were considered unsuitable for im- 
plantation and were discarded. 
Preoperative echocardiographic measurement 
(n = 43). The mean height of the anterior leaflets 
was 22 _+ 5 mm. The anteroposter ior d iameter of the 
mitral anulus was 26 _+ 4 mm. The distance separat- 
ing the plane of the mitral anulus and the apex of 
the papillary muscle was 22 _+ 5 mm. 
Early results 
Perioperative mortality and morbidity. Two early 
deaths resulted f rom severe biventricular failure 
despite normally functioning homografts. These pa- 
tients had severe preoperat ive contractile dysfunc- 
tion. In one, endocarditis was affecting a mitral valve 
prosthesis in a patient with systemic lupus erythem- 
atosus with poor ventricular function. The second 
patient had triple valve disease with systemic pul- 
monary hypertension and had previously undergone 
a mitral and tricuspid valve repair. 
One patient required an early reoperat ion at 10 
days. The patient, aged 76 years, had a staphylococ- 
cal bacterial endocarditis on a Starr-Edwards mitral 
prosthesis (Baxter Healthcare Corp., Edwards Div., 
Santa Ana, Calif.). The initial echocardiogram 
showed satisfactory results, but a rapid deterioration 
occurred at 10 days and necessitated reoperation. A
dehiscence of the homograft  was observed at the 
suture line attaching the leaflet tissue to the anulus 
in the region of the anterior commissure, probably 
caused by excess traction on the chordae. A St. Jude 
Medical mitral prosthesis (St. Jude Medical, Inc., St. 
Paul, Minn.) was inserted and the patient made a 
subsequent uneventful recovery. 
One patient had complete heart block that was 
completely resolved 3 weeks after the operation. 
One patient who had insertion of mitral and 
aortic homografts for acute bacterial endocarditis 
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Fig. 5. Surgical technique of mitral homograft implanta- 
tion: A, Resection of the diseased mitral valve. B, Division of 
the lateral attachments of the papillary muscles using trac- 
tion on the valve leaflets by division of muscular band. C, 
Positioning of the homograft papillary muscle into the slit 
between the native papillary muscle and the ventricular wall. 
was slow to regain consciousness after the operation 
because of a bacterial meningoencephalitis. This 
resolved with a minimal residual neurologic deficit. 
All other patients had uneventful postoperative 
courses. The average stay in the intensive care unit 
was 2.1 days. 
Early echocardiographic results. Echocardiographic 
results (transesophageal during the operation or 
transthoracic 2 months after the operation) revealed 
mitral insufficiency to be nonexistent (n = 21), 
minimal (n = 15), or mild (n = 6). The mean 
transvalvular g adient was 3 2 2 mm Hg. The mean 
surface area of the valve measured by planimetry 
was 2.5 2 0.3 cm 2 for patients having total ho- 
mograft replacement and 2.2 2 0.1 cm 2 for those 
having partial homograft reconstruction. 
Midterm results 
Functional status. All patients were examined af- 
ter a follow-up of 3 to 34 months (mean 14 2 3 
months). One patient died 5 months after the oper- 
ation of carcinoma. He had undergone partial ho- 
mograft replacement for an aseptic endocarditis 
with an inflammatory s ndrome that appeared to be 
related to advanced lung carcinoma. A postmortem 
examination was not available. 
One patient required reoperation at 22 months. 
She had continued to have symptoms after the 
operation (New York Heart Association class III) 
and echocardiography demonstrated mitral stenosis 
(surface valve area 1.4 cruz). This patient had un- 
dergone a partial homograft insertion and at reop- 
eration the native valve leaflet and chordae were 
found to be fibrotic and unpliable, causing stenosis. 
The valve was replaced with a St. Jude Medical 
mitral prosthesis. 
All 38 remaining patients had normal functional 
status, New York Heart Association class I (n = 25) 
and class II (n = 13). Thirty-three patients were in 
sinus rhythm and five patients were in atrial fibril- 
lation. 
Echography results. Transthoracic echocardiogra- 
phy revealed stable results when compared with 
results of earlier studies. Residual mitral insuffi- 
ciency was nonexistent (n = 20), minimal (n = 13), 
or mild (n = 5). No patient had moderate or severe 
insufficiency. The transvalvular gradient was 3 _+ 4 
mm Hg and the valve surface area measured by 
planimetry was 2.7 2 0.3 cm 2 after total homograft 
replacement and 2.5 + 0.4 cm 2 after partial ho- 
mograft reconstruction. 
Discussion 
In the early days of valvular surgery, replacement of
the mitral valve with a homograft by various ap- 
proaches was considered a promising surgical pro- 
cedure. 5'6 Nevertheless, attempts at heterotopic 
transplantation f a semilunar valve in the mitral 
position have provided isappointing results. 7 In the 
early 1960s, orthotopic transplantation of the mitral 
valve has been the focus of a number of animal 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 2 
Acar  et al. 373 
Fig. 5, Cont'd. D, Fixation of the papillary muscle: Mattress utures at the base secured by multiple 
interrupted sutures. E, Annuloplasty stitches placed before attachment of the homograft leaflets. F, 
Circumferential fixation of the homograft leaflets to the anulus. Continuous suture anchoring successively 
the posteromedial commissure, the anterior leaflet, the anterolateral commissure, and the posterior leaflet. 
G, Completed homograft eplacement of the mitral valve with an annuloplasty ring in place. 
experiments howing encouraging histologic re- 
sults. 1-3 However, clinical cases reported in the 
literature remained anecdotal and invariably re- 
sulted in early failure. 11' 12 More recently, tricuspid 
valve replacement with a mitral homograft has been 
performed by Pomar and Mestres. 13 On the other 
hand, continued evelopments in reparative surgery 
of the mitral valve using the principles described by 
Carpentier have allowed investigators to reexamine 
the feasibility of homograft replacement of the 
mitral valve. 14-16 
The selection of the size of the homograft is an 
important preliminary step in homograft replace- 
ment of a valve. Whereas the cylindric form of the 
aortic valve allows its size to be measured solely by 
the transverse diameter of the orifice, 6 the evalua- 
tion of the dimensions of the mitral valve is more 
difficult. Both the extent of valvular leaflet issue and 
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Fig. 6. Sites of partial homograft. 
that of the subvalvular pparatus must be taken into 
consideration. 
In our series the measurement chosen to size the 
leaflet tissue of the valve was the height of the 
anterior leaflet issue in its middle portion (see Fig. 
2). This was measured by preoperative transesoph- 
ageal echocardiographic study of a sagittal section 
of the mitral orifice (see Fig. 4). The height of the 
leaflet was measured in the open position (diastole) 
so as to dearly identify the free edge of the valve. In 
addition, the anteroposterior diameter of the mitral 
anulus in systole was measured (Fig. 4). The major- 
ity of patients in the series did not have deformation 
of the anulus (mitral stenosis, acute endocarditis); 
therefore the anteroposterior diameter of the anu- 
lus in systole was usually equivalent to the height of 
the anterior leaflet. In the absence of annular dila- 
tation, this measurement allowed confirmation of 
anterior leaflet sizing in patients in whom direct 
measurement was difficult because of pathologic 
alteration of the valve. 
Assessment of the dimensions of the subvalvular 
apparatus raised a difficult issue. At first, it was 
thought hat easily identifiable chordae, such as 
commissural or main chordae, would serve as a 
reference. However, the length of these chordae did 
not necessarily reflect hat of the neighboring chor- 
dae. The commissural chordae were sometimes 
short. Likewise, the main chordae could be long, 
often ending on the ventricular aspect of the valve 
well beyond the free margin. Finally, because of the 
pathologic process, the chordae might have length- 
ened as in degenerative processes or shortened as in 
rheumatic disease. For these reasons, it did not 
seem appropriate to evaluate the subvalvular appa- 
ratus with a view to homograft implantation using 
length of the chordae as a standard. 
At present, we believe that the best method of 
assessment is the measurement of the distance 
between the anulus and the apex of the papillary 
muscle. This parameter is not directly affected by 
any pathologic process involving the valve. It has the 
advantage of taking into consideration ventricular 
dilatation if present, which would indicate the need 
for a larger homograft. This parameter can be 
obtained by both direct measurement of the ho- 
mograff and echocardiographic study of the pa- 
tient's vane (see Figs. 2 and 4). Echocardiographic 
measurements of the valve were matched with those 
of the identification card of the homograft. A ho- 
mograft 3mm larger was selected to provide a slight 
excess of tissue and offer a large surface of coapta- 
tion. 
In this study, important technical modifications to
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Fig. 7. Partial mitral homograft implantation for calcific mitral stenosis: A, Localized calcification affecting 
the anterior commissure. B, Resection of the calcification with the underlying chordae. C, Partial mitral 
homograft showing theanterior commissure with adjacent portions of leaflets and subvalvular apparatus 
(arrow). D, Result after reconstruction with partial homograft and annuloplasty. 
previously described methods were developed con- 
cerning (1) the technique of fixation of the papillary 
muscle, (2) the systematic use of a prosthetic ring 
annuloplasty, and (3) operative strategy for partial 
homograft reconstruction. These developments 
were initially achieved in animal models. 
Contrary to various methods described in the 
literature, 11-13 which use an end-to-end fixation of 
homograft o native papillary muscles, we have 
adopted a different approach, using a side-to-side 
suture of the papillary muscles (see Fig. 5). The 
papillary muscle of the recipient was not amputated 
so that the maximum amount of viable myocardium 
remained to support the homograft. The native 
papillary muscle was mobilized by sectioning of the 
muscular bands attaching them to the ventricular 
wall (Fig. 5). The homograft papillary muscle was 
positioned into the slit between the native papillary 
muscle and the ventricular wall. It was then attached 
slightly deeper to the recipient. Contrary to other 
techniques,12, 13.17, 18 no material was used to rein- 
force the suture whether prosthetic (polytetraflu- 
oroethylene) or biologic (pericardium). On the basis 
of experience acquired through the technique of 
chordal shortening described by Carpentier, 1°we 
believe that the use of foreign material t the point 
of origin of the chordae can weakened their inser- 
tion and induce an appreciable risk of chordal 
erosion and rupture. This opinion is further corrob- 
orated by the experience with Biocor mitral biopros- 
theses (Bio-Vascular, St. Paul, Minn.), in which 
papillary muscles were carefully prepared with pros- 
thetic material and occasionally underwent early 
chordal rupture at their site of insertion on the 
papillary muscle. 19 
The papillary muscles of the homograft are un- 
avoidably subjected to several hours of ischemia 
immediately after retrieval and subsequently un- 
dergo significant stress during the cryopreservation 
process. It would be delusive to expect any viability 
of the grafted papillary muscle; shortly after implan- 
tation papillary muscles are fated to necrosis. His- 
tologic studies in transplanted valves in animals have 
shown progressive fibrotic reaction occurring within 
several weeks. 1-3 Sporadic areas of viable myocar- 
dium were observed that most likely corresponded 
to remnants of the native papillary muscle. 
The reliability of the technique of implantation 
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Fig. 8. Partial homograft implantation for acute endocar- 
ditis: A, Acute infective endocarditis with vegetations and 
valvular abscess. B, Partial mitral homograft showing the 
posteromedial hemivalve and its subvalvular apparatus 
(arrow). C, Result after partial replacement. Note the 
suture line between the native valve and homograft. 
used in this study depends on the healing process of 
the papillary muscles with progressive replacement 
with fibrotic tissue (see Fig. 1). This method con- 
trasts with a purely mechanical pproach involving 
interposition of prosthetic material or transfixing 
stitches a2 through the ventricular wall to counteract 
the physical stress. 
The respective positions of the different heads of 
the papillary muscle must be maintained atthe time 
of implantation to obtain an even distribution of 
traction on the leaflet tissue. Papillary muscles of 
the mitral valve have a great diversity in appearance. 
However, the analysis of a series of mitral valves 
retrieved from cadavers or from explanted hearts at 
the time of transplantation has allowed us to estab- 
lish a morphologic classification ofpapillary muscles 
to aid homograft implantation (see Fig. 3). This 
classification did not consider the shape of the 
muscle, be it rectangular o conical, thick or thin. It 
was based on the existence of one or several divi- 
sions of the papillary muscle and their sites with 
respect o the commissure. 
Four types of increasing complexity were de- 
scribed (see Fig. 3). Simple, undivided type I mus- 
cles constituted the largest group and their implan- 
tation did not present any technical difficulty. 
Divided muscles were typed according to the loca- 
tion of the plane of division: type II muscles were 
cleaved in a sagittal plane forming an individual 
head supporting the posterior leaflet, whereas type 
III were cleaved in a coronal plane forming an 
individual head supporting the commissure (Fig. 3). 
These two types were also easily transplantable so 
long as the orientation f the separate heads was 
preserved. Type IV papillary muscles were divided 
with multiple heads all originating at different levels 
within the ventricle (Fig. 3). In this group the 
commissural chordae were invariably short and orig- 
inated from a separate muscular band close to the 
mitral anulus. This arrangement raised such techni- 
cal difficulty that we recommend that this type of 
papillary muscle b discarded and the opposite half 
of the mitral valve used as a partial homograft, if
possible. 
In the cases of subdivision of the papillary muscles 
(types II and III), the respective position of the 
various heads was carefully maintained at the time 
of implantation. Uneven traction on any one head 
would lead to a commensurate prolapse or restric- 
tion of the opposite leaflet. This was prevented by 
joining the different heads while the homograft was 
being prepared before implantation. The head sup- 
porting the commissural chordae was used as a 
marker and fixed initially at the corresponding site 
alongside the native papillary muscle. The other 
heads were then sutured accordingly on each side of 
the commissure. 
Our experience has shown this method of implan- 
tation to be reliable at the short term and midterm. 
There have been no cases of rupture either of 
papillary muscle or chordae among the 43 patients, 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 2 
Acar et al. 377  
either early or late. One patient was reoperated on 
on the tenth postoperative day with mitral regurgi- 
tation caused by dehiscence of the valvular suture in 
a commissural rea. This complication was probably 
due to excessive traction on the subvalvular appara- 
tus. Previous mitral valve replacement with a pros- 
thesis had been performed and the ventricle was 
significantly dilated. Measurement of the distance 
from the apex of the papillary muscle to the mitral 
anulus was not available and the size of the ho- 
mograft had been roughly estimated from the diam- 
eter of the prosthesis. In general, the insertion of a 
mitral homograft for replacement of a prosthetic 
valve has not been satisfactory in this series (one 
death and one early reoperation). 
The proposed systematic use of a prosthetic an- 
nuloplasty ring in patients receiving a mitral ho- 
mograft represents a particularity of this study. The 
size of the ring selected was based on measurement 
of the anterior leaflet of the homograft with an 
obturator. We believe that annu!oplasty provides 
several advantages: (1) It permits precise adaptation 
of the size of the anulus to that of the homograft; 
(2) the semirigid structure of the ring absorbs ome 
of the mechanical stress exerted by ventricular con- 
traction and alleviates traction that would otherwise 
be directly applied on the valvular suture line; 
(3) ring annuloplasty allows a greater surface of 
leaflet coaptation, thereby lowering the tension on 
the subvalvular apparatus. The slight overcorrection 
achieved by annuloplasty may compensate for im- 
perfections in the regulation of tension of the chor- 
dae. 
The idea to partially replace the mitral valve with 
a portion of homograft is not new. In 1964, while 
working at Broussais Hospital, Cachera and associ- 
ates 3 introduced the concept of partial homograft 
replacement. They studied varied techniques of 
mitral valvuloptasty: (1) grafting of a patch of ho- 
mologous leaflet tissue, (2) replacement of the 
entire anterior leaflet with its subvalvular apparatus 
using the corresponding portion of a homograft, and 
(3) total homograft replacement. More recently, 
Revuelta nd coworkers, 3 in a study using an animal 
model and scanning electron microscopy, demon- 
strated the perfect integration of a partial homograft 
when placed amid native mitral tissue. 
Use of a partial mitral homograft should be 
considered as part of the wide range of techniques 
of mitral valve repair. It is technically feasible to use 
biologic material (autologous pericardium) to re- 
constitute a portion of mitral valve leaflet issue, and 
it is also possible to replace several chordae either 
by chordal transposition or with prosthetic hor- 
dae.lO, 21 However, the presence of a voluminous 
pathologic process that affects both leaflet issue and 
chordae, especially when involving a commissural 
region, represents a serious limitation to valve re- 
construction. 22-24 This situation is met most fre- 
quently in two conditions, mitral stenosis with calci- 
fication and acute bacterial endocarditis with 
localized abscess formation and vegetations. In our 
series, 21 patients with either of those indications 
underwent partial homograft replacement. The re- 
mainder of the valve must be normal, because a 
diseased remnant may lead to a mediocre result 
(one patient in this series). 
Technically, we believe it is preferable to divide 
the valve vertically with the aim of replacing a 
commissural region or a hemivalve, rather than 
dividing the valve along the horizontal axis and 
replacing an entire leaflet. A vertical division allows 
selective replacement of 25% to 50% of the valve 
according to the extent of the lesion. A distinct 
advantage is that only one papillary muscle needs to 
be reimplanted. Also, valve closure results from 
coaptation between two leaflets of the same origin 
belonging either to the homograft or to the native 
valve. 
Transplantation of an entire leaflet (four cases) 
does not appear to be fully satisfactory and presents 
certain drawbacks. Both papillary muscles must be 
reimplanted and exposure is made more difficult by 
the presence of the opposing leaflet and its chordae. 
Afterward, the presence of a suture line in the 
region of the commissures can impair the opening of 
the valve. Furthermore, valve closure results from 
apposition between the homograft and the opposite 
native leaflet, and the mildest asymmetry in chordal 
tension may lead to relative prolapse. Although 
none of the patients having undergone this type of 
repair have required reoperation, we no longer 
recommend its use. In the presence of lesions 
invading a whole leaflet, the entire mitral valve is 
replaced. 
Homograft replacement of the mitral valve may 
be considered an extension of valvular reconstruc- 
tive surgery. The theoretic advantages are multiple: 
cryopreserved homologous tissue has been shown to 
remain viable 25 and its longevity is probably superior 
to that of glutaraldehyde-treated issue. It is a 
biologic material and does not require anticoagula- 
tion. In this method of mitral valve replacement the 
subvalvular apparatus is preserved, so that its im- 
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portant role in ventricular function is retained. 26 
The mitral homograft may represent an interesting 
alternative in children, as shown in two patients in 
this series. However, long-term results with func- 
tional assessment of the transplanted valves are 
awaited before more liberal use of mitral ho- 
mografts can be recommended. 
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Discussion 
Mr. Magdi Yacoub (London, England). There is no 
doubt that the ideal valve substitute in the mitral position 
is another mitral valve, because the mitral valve apparatus 
is a sophisticated structure that changes its shape and 
dimensions instantaneously t ° achieve excellent function 
during both systole and diastole. 
I have a few questions. First, is it necessary to use an 
anulus or a ring, because that will interfere with the 
function of the mitral valve? Second, what do you think is 
the fate of the muscular part left in the papillary muscle? 
In the early 1970s we used a similar technique. We were 
worried about necrosis of the muscular parts of the 
papillary muscle and whether that will elongate, and we 
used to cover it with pericardium. Can you give us your 
ideas about that? I have two other technical points, as 
well. Do you use the aortic homograft from the same 
donor heart, and if you do, how do you avoid encroaching 
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on the anterior cusp of the mitral valve? Finally, how do 
you make sure that the orientation of the attachment of 
the chordae is such that the tension will be distributed 
equally around these chordae? 
Dr. Aear. Sir Magdi, we all are aware of your great 
contribution in cardiac surgery, and particularly in the 
field of homografts. Concerning the need for annulo- 
plasty, we believe that ring annuloplasty is a very impor- 
tant addition to mitral homografts. In fact. it absorbs part 
of the mechanical stress that otherwise would be exerted 
directly on the valvular suture line. Also it allows the size 
of the recipient anulus to be adapted precisely to that of 
the homograft. Finally, use of ring annuloplasty allows an 
increase in the surface of leaflet coaptation: thereby, it 
reduces the traction on the subvalvular apparatus and on 
the sutured papillary muscles. 
Concerning the outcome of these papillary muscles. 
because of the ischemic process and the cryopreservation 
process, they will become necrotic. Moreover, the reliabil- 
ity of the technique of implantation is based on the 
healing process of the papillary muscle with progressive 
fibrosis. 
At present, the technicians at the Assistance Public 
Tissue Bank in Paris are well experienced and are able to 
harvest both the mitral and the aortic valves. Sometimes 
some tissue at the insertion of the anterior mitral eaflet is 
kept attached to the aortic valve. This does not compro- 
mise the use of both valves as homografts. 
Your last question concerned the proper orientation of 
the papillary muscle during implantation. We use the 
commissural chordae as a landmark, which is usually 
easily identified. The head supporting the commissural 
chordae is placed at the corresponding location on the 
recipient's papillary muscle. Then all the other heads are 
sutured accordingly. 
Dr. Jos~ L. Pomar (Barcelona, Spain). I would like to 
congratulate Dr. Acar and associates for their courage in 
this reattempt o solve the problem of replacing the 
atrioventricular valves with mitral homografts. 
We have used eryopreserved mitral homografts to 
replace the tricuspid valve in four patients ince 1991. The 
four patients had right heart endocarditis induced by their 
heroin addiction. In all of them antibiotic therapy was 
unsuccessful. The preoperative CD4 count was high 
enough to assume a life expectancy of more than 7 to 10 
years. 
The technique initially described by us does not sub- 
stantially differ from that showed by Dr. Acar and his 
group. However, in our technique no prosthetic rings were 
used and only an autologous pericardial strip was used to 
reinforce the suture to the posterior leaflet. 
In this small series there have been no deaths. A 
complete primary cur e of the endocarditis was achieved in 
all patients. One patient had a new episode of endocar- 
ditis more than 12 months after the transplantation, but 
this was successfully treated as a native valve infection. 
The patients have remained free of symptoms for up to 4 
years. The postoperative d gree of valve regurgitation has 
not changed since the time of the operation. The subval- 
vular structures eem to stay in place. 
I have a couple'of questions for Dr. Acar: 
We also have replaced the valve in patients with acute 
disease in whom the ventricular dimensions were close to 
normal. On the contrary, you have implanted some ho- 
mografts in patients with chronic rheumatic disease, in 
whom the left ventricular dimensions are supposed to 
recover once the valve becomes competent. Regarding the 
length of the chordae and papillary muscles, what is your 
feeling about the long-term behavior of the implanted 
grafts as the ventricular size regresses in time? 
The second question concerns the fact of using a 
Carpentier annuloplasty ring in the setting of an active 
infection. Do you believe it is absolutely necessary to 
support he graft with a ring or can that be avoided when 
the graft versus host perimeter and shape mismatch are 
negligible? 
Dr. Acar. We performed echocardiography in our study 
both immediately after the operation and as long as 34 
months after the operation. We have not observed any 
recurrence of insufficiency or progression of a residual 
leak, even in patients Whos e ventricle recovered to normal 
size. Use of the mitral homograft can be considered as an 
extension of mitral valve reconstruction because it ad- 
heres to the same principles. After reconstruction, once a 
valve has become competent, he echocardiographic re-
sults usually remain stable even though the ventricle 
resumes a normal size and a normal shape. 
We already mentioned that the use of a ring is a very 
important addition to mitral homografts. We have used a 
ring for mitral valve repair in patients with acute endo- 
carditis, and we have not observed that recurrence ismore 
prevalent with this operation than with other types of 
surgical procedures in this setting. 
Dr. Radu C. Deae (Targu-Mures, Romania). One way to 
improve the late results of mitral valve replacement, less 
optimal than those of aortic valve rePlacement, is to use a 
stentless mitral valve substitute with the known features of 
the normal mitral valve: large diastolic opening, continuity 
to the papillary muscle, and contraction of the posterior 
left ventricular wall around the mitral anulus. As the 
authors showed, use of a mitral homograft is one of the 
ways to improve results. In the 1960s Ross and Senning 
used such mitral homografts with limited success. Could 
you identify those factors that allowed you to obtain 
superior results? One of the keys to making the valve 
competent on the operating table is adequate sizing and 
the technique of suturing at the papillary muscle, as you 
mentioned. 
I would like to Support the principle of the stentless 
mitral valve. From our experience with the stentless mitral 
valve made of stabilized auto!ogous pericardium, used in 
19 patients from 1989, we had one case in which the suture 
at the papillary muscle broke loose and another case in 
which late endocarditis developed, and both necessitated 
re-replacement. All the other patients had competent 
valves from the operation up to 72 months, nearly 7 years 
after the operation. 
The main feature of the valve used was a large orifice 
area of 4.36 and a valve index superior to the standard 
mentioned in the literature. With our technique we man- 
aged to have secure sutures of the papillary muscle and 
anulus. 
The patients operated on in our series enjoy a normal 
life with a remarkable exercise capacity, probably because 
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of the large orifice area and continuity to the papillary 
muscle. 
Dr. Aear. You ask why the technique seems to be 
effective now whereas it failed years ago. I think two 
modifications made this technique more reliable. 
The first modification is the method of papillary muscle 
implantation itself, in which a side-to-side suture is used 
without pledgets. We think that this method contrasts with 
a purely mechanical approach involving polytetrafluoro- 
ethylene pledgets or transfixing stitches through the ven- 
tricular wall as described earlier. Our technique relies 
more on the healing process of the papillary muscle. 
The second point is the appropriate matching between 
the homograft and the native valve. Even sophisticated 
measurements can provide only an estimate of the size of 
the valve, and it is very important o provide a certain 
degree of hypercorrection to compensate for imperfec- 
tion. This is achieved by using both a slightly larger 
homograft than the valve size and ring annuloplasty. 
Dr. Charles A. Yankah (Berlin, Germany). I would like 
to make some comments from our experience in Kiel, 
Germany, some years ago, which will highlight he prob- 
lems regarding the immunologic and technical aspects of 
mitral allograft surgery. 
Professor Bernhard had operated on three patients 
using viable grafts received from the Harefield Hospital 
homograft laboratory. One patient's graft was explanted 
with strong infiltrations of inflammatory cells and macro- 
phages, as well as identified T-lymphocytes of CD4 sub- 
types. We believe that if a viable graft is used, which is 
antigenic, it will clearly obey the rules of transplantation 
biology. Such changes are to be expected, and these 
changes are going to affect the tissue, which will then 
cause some structural changes. 
Two of our patients had chordal ruptures. The third 
patient was a 64-year-old woman whose mitral homograft 
was in place for about 44 months, and eventually she had 
a papillary muscle rupture rather than a chordal rupture. 
All three patients underwent uneventful reoperations with 
prosthetic valve replacement. We have therefore identi- 
fied two potential weak points for early valve failure. We 
believe that besides using the annular ing support, which 
we did not use in our patients because they all had mitral 
stenosis, one has to support he chordae as well as the 
anastomotic site of the graft-recipient papillary muscles, 
tO reinforce the very important potential sites of compli- 
cations that could cause early or late postoperative alve 
dysfunction. Our word of caution is that these two tech- 
niques should he considered: chordal support, which Dr. 
Vetter in Munich has demonstrated to be very effective, 
and transpapillary-epicardial suture support. 
Dr. Acar, do you think these supports are very relevant 
for long-term durability of your homografts? How do the 
chordae and the structures readapt hemselves when you 
have large ventricles, which might undergo a postopera- 
tive remodeling process with dimensional changes? 
Dr. Aear. The late outcome of this type of procedure 
obviously remains unknown. The histologic structure of 
the chordae is very close to that of the leaflet tissue. We 
hope that mitral homografts will provide results compa- 
rable with those of aortic homografts. 
I would like to make one last comment concerning the 
use of transfixing stitches with pledgets for papillary 
muscle implantation. We believe that the use of prosthetic 
material at the level of the papillary muscle in fact can be 
dangerous and can lead to progressive erosion and weak- 
ening of the chordae. In this series, there was no chordal 
rupture or papillary muscl e dehiscence. 
